Quan Vu brings more than 20 years of “hands-on” healthcare business executive experience with an emphasis on corporate & business development, strategy, finance and operations. He possesses a demonstrated history of prospecting, evaluating, structuring and closing transactions that augment both organizational and shareholder value. He’s also a strategist with a sound understanding of pipeline development, commercial assessment and go-to-market strategies. An adept finance professional, Quan has consummated billions of dollars in capital raises and M&A deals for public and private companies. He’s also an operator proficient at navigating complex situations, identifying improvement opportunities and propelling enterprise-wide changes to optimize performance.
In the past two years prior to joining 180 Life Sciences, Quan held several concurrent leadership roles. He served as the CEO of Baleena Bioscience, a consolidator of several healthspan biotechnology/medical device assets with the express purpose of going public via a SPAC. Additionally, he served as a Managing Director and Co-Head of Healthcare IT for Solganick & Co., a boutique technology investment bank providing M&A advisory. He also provided interim CFO/CBO consulting services, including private capital raises and out-licensing, as a member of LS Associates, a division of LifeSci Partners.
Before his roles above, Quan served as Vice President of Strategy & Corporate/Business Development at Opiant Pharmaceuticals, a public company focused on addiction and drug overdose, where he directly facilitated the company’s growth from 3 to 16 FTEs and from $10M to $60M market capitalization in under three years. Prior to Opiant, he served as a Staff Vice President at Anthem with responsibilities for strategy, planning and administration, including the management of a $2.2B IT budget. Prior to Anthem, he held leadership roles at Impax Laboratories and Amgen as a Director and Senior Manager, respectively, with responsibilities that encompassed strategy, corporate/business development and finance.
Quan began his career in financial and economic consulting at LECG and in healthcare corporate finance and M&A at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. He obtained his BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).
How do I contact Quan Anh Vu?
Has Quan Anh Vu been buying or selling shares of 180 Life Sciences?
Quan Anh Vu has not been actively trading shares of 180 Life Sciences over the course of the past ninety days. Most recently, on Thursday, December 16th, Quan Anh Vu bought 21 shares of 180 Life Sciences stock. The stock was acquired at an average cost of $1,512.40 per share, with a total value of $31,760.40. Learn More on Quan Anh Vu's trading history.
Who are 180 Life Sciences' active insiders?